论文部分内容阅读
胡汝银、高明华、董登新等热议独董陷入灰色政商关系5月26日,天目药业(600671.SH)第三大股东杭州现代联合投资有限公司提名罢免两位独立董事。此前,这两位独立董事对天目药业2013年年报中的财务数据真实性提出质疑,并投下反对票。目前,这一针对“不听话”独董的罢免案已引发上交所的发文质询,要求天目药业补充罢免两位独立董事的具体理由和依据。这次罢免独董的闹剧将独立董事的尴尬推向前台。所谓独立董事,是相对于参与上
May 26, Tianmu Pharmaceutical (600671.SH), the third-largest shareholder Hangzhou Modern United Investment Co., Ltd. nominated to remove two independent directors. Earlier, the two independent directors questioned the authenticity of the financial data in the 2013 annual report of Tianmu Pharmaceutical and voted against it. At present, this dismissal of the “independent director” directed at “disobedience” has triggered a question raised by the Shanghai Stock Exchange asking Tianmu to add specific reasons and basis for removing the two independent directors. The recall of the director’s farce pushed the embarrassment of independent directors to the forefront. The so-called independent directors, is relative to the participation